| ²é¿´: 3017 | »Ø¸´: 32 | |||||||||||||||||
| ¡¾Óн±½»Á÷¡¿»ý¼«»Ø¸´±¾Ìû×Ó£¬²ÎÓë½»Á÷£¬¾ÍÓлú»á·ÖµÃ×÷Õß redkey65 µÄ 23 ¸ö½ð±Ò £¬»ØÌû¾ÍÁ¢¼´»ñµÃ 1 ¸ö½ð±Ò£¬Ã¿ÈËÓÐ 1 ´Î»ú»á | |||||||||||||||||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||||||||||||||||
[½»Á÷]
»ÔÈðÎ人Ñз¢ÖÐÐijÏÕÐÁÙ´²ÊÔÑéÖúÀí£¨ÄÚ²¿ÍƼö£©¼±ÕÐ6ÈË£¡
|
|||||||||||||||||
ÎÒÃÇÊÇÕâÀ»ÔÈðÎ人Ñз¢ÖÐÐÄ×øÂäÓÚ·ç¾°ÓÅÃÀµÄ¹â¹ÈÉúÎï³Ç£¬Ä¿Ç°ÓÐ700+Ô±¹¤¡£Ð½×ʸ£Àû²»»á²î£¬¿É°Ù¶ÈÁ˽⡣ ÎÒÃÇÔÚÕâÀÎÒÃÇÊÇÓзç¶ÈÒ²ÓÐζȵÄteam£¬manager³¬¼¶nice¡£½üÆÚÒµÎñSample TextÀ©ÕÅ£¬ÓÐ6¸ö¿Õȱְ룬¼±ÐèÈË¡£»¶Ó¸÷λӻԾ×Ô¼ö»òÍÆ¼ö¡£ ÎÒÃÇÆÚ´ýÄ㣬¼È¶ÁµÃ¶®Ó¢ÎÄÎÄÏ×£¬Óֻظ´µÃÁËÓ¢ÎÄÓʼþ¡£Ó¢ÎĶÁд²»³ÉÎÊÌ⣻¿´²»Ì«¶®ÏÂÃæµÄÖ°ÎñÃèÊöû¹ØÏµ£¬ÎÒÃÇÓÐÍêÉÆµÄÅàѵ»úÖÆÀ´°ïÖúÄã¿ìËÙÁ˽⡣ ÎÒÃÇÏ£ÍûÄ㣬ÄÚÏòÍâÏò¶¼ok£¬Ö»ÒªÄܾ²ÏÂÐÄÀ´×öÊÂÇ飬ϲ»¶°ì¹«ÊҰ칫ģʽ¼´¿É£¬Õ¾×Å»ò×ø×ÅËæÒâ¡£ÆäËûµÄ¿´ÑÛÔµ°É£¬Ëµ²»¶¨ÎÒÃǾͱ˴˿´¶ÔÑÛÇ©offerÁËÄØ¡£ ÎÒÃǰïÖúÄ㣬ȫ·½Î»Á˽âÁÙ´²ÊÔÑéµÄÕû¸öÁ÷³Ì£¬Ö¾´æ¸ßÔ¶µÄÄ㻹¿ÉÒÔ´ÓÖúÀíÆð²½£¬×öµ½ÏîÄ¿¾ÀíStudy Manager/ Clinical Project ManagerÖ¸ÈÕ¿É´ýѽ¡£ ¹¤×÷ÀàÐÍ£º ÕýʽԱ¹¤ / Regular ÁªÏµ·½Ê½: redkey3@sina.com£»ÖÐÓ¢ÎļòÀú¾ù¿É£¬Ó¦½ìÍù½ì¶¼»¶Ó£¡ »ù±¾Á÷³Ì£º ¼òÀúÍÆ¼ö---°²ÅÅµç»°ÃæÊÔ----±ÊÊÔ----·¢·Åoffer£¨Ð½³êºÍÈëְʱ¼ä£©---ÕýʽÈëÖ° Ö°ÎñÃèÊö£º Partners with the Clinical Study Team Lead to provide study level operational and logistical support to clinical study teams to ensure the timely and efficient execution of clinical trials and compliance with ICH-GCP, SOP, and regulatory requirements. Works proactively and independently to coordinate and prioritize multiple key study tasks in support of clinical trial systems and processes. Collaborates with global cross functional study team members of varying levels of seniority. Uses established procedures and methodologies to ensure the completion of assigned tasks according to timelines and to required quality standards. Has fundamental knowledge of the principles and concepts related to the CSTA role. [ À´×Ô°æ¿éȺ ºþ±± ] |
» ²ÂÄãϲ»¶
²ÄÁϵ÷¼Á£¬307·Ö
ÒѾÓÐ16È˻ظ´
0817»¯Ñ§¹¤³ÌÓë¼¼Êõ¿¼ÑÐ312·Öµ÷¼Á
ÒѾÓÐ3È˻ظ´
282·Ö²ÄÁÏרҵÇóµ÷¼ÁԺУ
ÒѾÓÐ25È˻ظ´
²ÄÁÏÓ뻯¹¤ 323 Ó¢Ò»+Êý¶þ+Îﻯ£¬Ò»Ö¾Ô¸£º¹þ¹¤´ó ±¾È˱¾¿ÆË«Ò»Á÷
ÒѾÓÐ4È˻ظ´
268Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸»ªÖÐʦ·¶071000£¬325Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
070303Ò»Ö¾Ô¸Î÷±±´óѧѧ˶310ÕÒµ÷¼Á
ÒѾÓÐ3È˻ظ´
0856»¯¹¤ÔÀí
ÒѾÓÐ6È˻ظ´
²ÄÁÏר˶274Ò»Ö¾Ô¸ÉÂÎ÷ʦ·¶´óѧÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
274Çóµ÷¼Á0856²ÄÁÏ»¯¹¤
ÒѾÓÐ13È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
ÓлúºÏ³É¸ÚλÕÐÆ¸
+1/879
¸£½¨Å©ÁÖ´óѧ²ÄÁϹ¤³ÌѧԺ-»Æ±ë½ÌÊÚ¿ÎÌâ×éÕÐÊÕµ÷¼Á˶ʿÑо¿Éú
+3/601
±«ºìÀö¿ÎÌâ×é Ñо¿ÉúÕÐÉúÆôÊÂ
+1/481
×ø±ê¹ãÖÝ£¬Õ÷Å®ÓÑ
+2/126
º£ÄÏ´óѧÇñÌìÓîÀÏʦÍŶÓÕÐÊÕ²©Ê¿ÉúÓëÕÐÆ¸²©Ê¿ºó
+5/105
Àä¶³ÐÐÐÇÇòÄ¥»ú¡¢µÍθßÎÂÇòÄ¥»ú
+1/90
ÕÐ˶ʿµ÷¼ÁÉú
+2/88
Ö£ÖÝ´óѧ¸¶ÓÀÖù¿ÎÌâ×é³ÏÕÐ2026ÄêÈëѧ²©Ê¿Éú
+1/83
ÕÒ¹¤×÷¾ÑéÇóÖú
+1/40
¹ã¶«¹¤Òµ´óѧ¹ÜÀí¿ÆÑ§Ó빤³Ìרҵ²©Ê¿ÕÐÉú
+1/35
ÉîÛÚ´óѧ»úµçÓë¿ØÖÆ¹¤³ÌѧԺ³ÏÕÐÏȽøÖÆÔì¡¢¼¤¹â¼Ó¹¤¡¢Ôö²ÄÖÆÔì¡¢ËÜÐÔ³ÉÐεÈÁìÓò²©Ê¿ºó
+1/12
Ó¢¹ú°£¿ËÈûÌØ´óѧ & ·¨¹ú°ÍÀèÈø¿ËÀ×´óѧÁªºÏÅàÑø²©Ê¿
+1/9
Î÷¾©Ñ§ÔºÍÁľˮÀû 2026 ¼¶Ñо¿ÉúÕÐÉúÏà¹ØËµÃ÷
+1/8
¡¾Éñ¾ÉúÎïѧ¿¼²©ÇóÖú¡¿
+1/7
¸´µ©´óѧ¼¯³Éµç·ѧԺ³ÌÔö¹â¿ÎÌâ×鼱Ƹ¿ÆÑÐÖúÀí
+1/7
26Ä격ʿÕÐÉú
+1/6
ҩѧר˶һ־ԸËմ󱾿ÆËÕ´óѰÇóBÇø¸ßУµ÷¼ÁÃû¶î
+1/3
339Çóµ÷¼Á
+1/2
˫һÁ÷Ìì½ò¹¤Òµ´óѧµçÐÅѧԺÀîºèÇ¿½ÌÊÚÕÐÊÕ2026ÄêÉêÇëÉóºËÖÆ²©Ê¿3Ãû
+1/1
°Ä´óÀûÑÇ¿ÆÑ§ÔºÔºÊ¿Prof.Gordon Wallace, University of Wollongong È«½±²©Ê¿»ú»á
+1/1
29Â¥2021-06-12 12:32:01
4Â¥2021-05-25 17:30:06
ÏùÕŵij¬³¬
Ìú¸Ëľ³æ (ÎÄ̳¾«Ó¢)
- Ó¦Öú: 40 (СѧÉú)
- ½ð±Ò: 3396.8
- Ìû×Ó: 20848
- ÔÚÏß: 2802.1Сʱ
- ³æºÅ: 3860801
7Â¥2021-05-25 19:56:10
¼òµ¥»Ø¸´
dxmboy882Â¥
2021-05-25 17:28
»Ø¸´
bjdxyxy3Â¥
2021-05-25 17:29
»Ø¸´
redkey65(½ð±Ò+1): лл²ÎÓë
¡£ ·¢×ÔСľ³æAndroid¿Í»§¶Ë
ʯͷ°¢´ô5Â¥
2021-05-25 17:33
»Ø¸´
redkey65(½ð±Ò+1): лл²ÎÓë
. ·¢×ÔСľ³æIOS¿Í»§¶Ë
tzynew6Â¥
2021-05-25 17:34
»Ø¸´
redkey65(½ð±Ò+1): лл²ÎÓë
9 ·¢×ÔСľ³æAndroid¿Í»§¶Ë
nono20099Â¥
2021-05-25 20:40
»Ø¸´
redkey65(½ð±Ò+1): лл²ÎÓë
¡£ ·¢×ÔСľ³æAndroid¿Í»§¶Ë
Sleep1110Â¥
2021-05-25 20:59
»Ø¸´
redkey65(½ð±Ò+1): лл²ÎÓë
£¬ ·¢×ÔСľ³æIOS¿Í»§¶Ë
zhanglang9312Â¥
2021-05-25 23:45
»Ø¸´
redkey65(½ð±Ò+1): лл²ÎÓë
£¬ ·¢×ÔСľ³æAndroid¿Í»§¶Ë
yuanbingzhan14Â¥
2021-05-26 07:11
»Ø¸´













»Ø¸´´ËÂ¥